US-based GenScript Biotech Corporation has expanded its cGMP manufacturing capacity for single guide or sgRNA and non-viral DNA payloads with a new, state-of-the-art facility in Zhenjiang, Jiangsu, China. This latest expansion provides biopharma companies and gene and cell therapeutic discovery startups a fast-turnaround source of the quality components needed to advance novel therapies from the bench to the clinic and onto the market in less time.
This recent expansion adds 400,000 sq.ft. of cGMP manufacturing space in Zhenjiang, bringing onstream four additional production lines equipped to deliver up to gram quantities of sgRNA or hundreds of milligrams of ssDNA or dsDNA per batch, respectively, with superior purity.
In 2020, GenScript established a 21,500 sq. ft. cGMP plant in Nanjing, comprising five cGMP production lines for synthetic CRISPR sgRNA and non-viral DNA payloads. As of April 2023, GenScript has delivered 56 batches of cGMP-quality gene editing products to global biotechnology and pharmaceutical companies in the gene and cell therapy field, supporting 18 project applications, 5 of which have received IND approvals.
